Plasma CA125 concentrations (U/mL) were determined using the ARCHITECT CA 125 II assay (Abbott Laboratories, Abbott Park, IL), a chemiluminescent microparticle immunoassay run on the ARCHITECT i System. Measurements on all study samples in both cohorts were conducted in the Department of Pathology and Laboratory Medicine at Roswell Park Comprehensive Cancer Center.
Architect ca125 2
Manufactured by Abbott
Sourced in Japan, United States
The ARCHITECT CA125 II is an automated immunoassay analyzer designed for the quantitative determination of cancer antigen 125 (CA125) levels in human serum and plasma samples. It utilizes chemiluminescent microparticle immunoassay (CMIA) technology to measure CA125 concentrations.
Automatically generated - may contain errors
5 protocols using architect ca125 2
1
CA125 Measurement in Cancer Patients
2
Tumor Marker Analysis in Surgical Samples
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
Samples were collected from all the patients prior to surgery using blood collection tubes without anticoagulants. Each blood sample was centrifuged at 3000 rpm and stored at −80 °C until use. Tumor markers including CA125 (ARCHITECT CA125 II, Abbott Japan LLC, Tokyo, Japan), CA19-9 (CL AIA-PACK® SLa, Tosoh Corporation, Tokyo, Japan), CEA (CL AIA-PACK® CEA, Tosoh Corporation, Tokyo, Japan), and HE4 (ARCHITECT HE4, Abbott Japan LLC, Tokyo, Japan) were measured using a chemiluminescence immunoassay, according to the manufacturer’s instructions. Serum samples in dry ice were transported to the Tosoh diagnostics product divisions (Tosoh Corporation, Kanagawa, Japan), and CA19-9 and CEA concentrations were determined immediately. HE4 and CA125 (ARCHITECT CA125 II) were measured at BML INC., Tokyo, Japan. In case of CA125 and HE4 levels under the limit, we recorded the lower limit of calibration as 1 (U/mL) and 20 (pmol/L), respectively. Measurements were performed by clinical laboratory technologists who were blinded to the study.
3
Biomarker Quantification Techniques
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
N‐terminal pro‐brain natriuretic peptide and hs‐TnT levels were determined by electrochemiluminescence immunoassays using a Cobas E601 platform (Roche Diagnostics, Switzerland). Interleukin 1 receptor‐like 1 (ST2) was measured based on immunoturbidimetry using the SEQUENT‐IA reagent kit (Critical Diagnostics, Ireland), on an AU‐5800 platform (Bekman Coulter, Ireland). CA‐125 was measured using the ARCHITECT CA‐125 II chemiluminescent microparticle immunoassay (CMIA), on the ARCHITECT i System (Abbott Laboratories).
4
Biomarker Quantification in Ovarian Cancer
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
The sampling of the peripheral blood was performed under the standard procedure from the cubital vein, using 7.5 mL tubes of S-Monovette® Serum Gel (Sarstedt) preoperatively, once or twice during the follow-up period and always when recurrence was suspected. The samples were transported to the Department of Clinical Biochemistry UH Brno, where the serum was separated by centrifugation, and the samples were analyzed either immediately (CA125, HE4) or stored frozen at −80 °C until analysis (DJ1 and L1CAM).
The quantitative assessments of L1CAM and DJ1 levels were performed by enzyme-linked immunosorbent assay (ELISA) using ELISA reader iMARK (Bio-Rad). For L1CAM, kit CN MBS 2023094 (MYBioSource, USA) was used. DJ1 serum levels were measured using kit CN CY-9050V2 (CircuLex MBL, UK). The serum concentrations of HE4 and CA125 were determined using quantitative, chemiluminescent microparticle immunoassay (CMIA) on the analyzer Architect i2000 (Abbott, Abbott Laboratories, USA). For CA125 measurement, the diagnostic set ARCHITECT Ca125 II (CN 2K45-24, Abbott) was used. HE4 serum level assessments were performed using the diagnostic set ARCHITECT HE4 (CN 2P51-25, Abbott).
The quantitative assessments of L1CAM and DJ1 levels were performed by enzyme-linked immunosorbent assay (ELISA) using ELISA reader iMARK (Bio-Rad). For L1CAM, kit CN MBS 2023094 (MYBioSource, USA) was used. DJ1 serum levels were measured using kit CN CY-9050V2 (CircuLex MBL, UK). The serum concentrations of HE4 and CA125 were determined using quantitative, chemiluminescent microparticle immunoassay (CMIA) on the analyzer Architect i2000 (Abbott, Abbott Laboratories, USA). For CA125 measurement, the diagnostic set ARCHITECT Ca125 II (CN 2K45-24, Abbott) was used. HE4 serum level assessments were performed using the diagnostic set ARCHITECT HE4 (CN 2P51-25, Abbott).
5
Quantification of HE4 and CA125 Biomarkers
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
This study used ARCHITECT HE4 and ARCHITECT CA125 II (Abbott Laboratories, Abbott Park, IL, USA). The samples were thawed, inverted, mixed immediately before use, and centrifuged at 4°C and 2,000×g for 50 minutes. The samples were analyzed in accordance with the package inserts. If a sufficient sample amount was available and the sample was over the measurement range, automatic or manual dilution was performed according to the package insert, and the diluted sample was measured again.
About PubCompare
Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.
We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.
However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.
Ready to get started?
Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required
Revolutionizing how scientists
search and build protocols!